1229022-83-6
1229022-83-6
Chemical Structure
Secukinumab
Synonym(s): AIN457
- CAS. Nr.: 1229022-83-6
- Formula:N/A
- Molecular Weight:(147.82 kDa)
SMILES: [Secukinumab]
Biological Activity: Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Secukinumab | 98.9% | Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Secukinumab (Anti-Human IL-17A) | 98.31% | Secukinumab (Anti-Human IL-17A) is a fully human anti-interleukin-17A monoclonal antibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Shirley M, et al. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2016;76(11):1135-1145. [Content Brief]
- [2]. Reich K, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304-315. [Content Brief]
